EQRx, Inc. (EQRX)

NASDAQ: EQRX · IEX Real-Time Price · USD
3.78
+0.27 (7.69%)
At close: Dec 2, 2022 4:00 PM
3.60
-0.18 (-4.76%)
After-hours: Dec 2, 2022 7:02 PM EST
7.69%
Market Cap 1.71B
Revenue (ttm) n/a
Net Income (ttm) -145.69M
Shares Out 475.57M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,134,446
Open 3.5
Previous Close 3.51
Day's Range 3.44 - 3.86
52-Week Range 2.63 - 9.98
Beta n/a
Analysts Sell
Price Target 4.15 (+9.8%)
Earnings Date Nov 10, 2022

About EQRX

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinic... [Read more]

Industry Biotechnology
Founded 2019
CEO Melanie I. Nallicheri
Employees 240
Stock Exchange NASDAQ
Ticker Symbol EQRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for EQRX stock is "Sell." The 12-month stock price forecast is 4.15, which is an increase of 9.79% from the latest price.

Price Target
$4.15
(9.79% upside)
Analyst Consensus: Sell
Stock Forecasts

News

EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in...

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the m...

1 day ago - GlobeNewsWire

A Biotech Steps Back From Bold Plan to Drop Drug Prices. A Stunning Selloff.

Share of EQRx plunged 28.6% after the drugmaker said it would sell two cancer drugs at market prices, instead of the cut-rate prices it had promised.

3 weeks ago - Barrons

Why EQRx Shares Dropped 28.62% on Thursday

The company suspended trials for one of its lead therapies.

3 weeks ago - The Motley Fool

Why Earnings Season Could Be Great for EQRx (EQRX)

EQRx (EQRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 weeks ago - Zacks Investment Research

EQRx to Participate in the Jefferies 2022 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantial...

3 weeks ago - GlobeNewsWire

EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022

CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantial...

1 month ago - GlobeNewsWire

EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically l...

3 months ago - GlobeNewsWire

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugem...

CAMBRIDGE, Mass., Aug. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically l...

3 months ago - GlobeNewsWire

EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regula...

CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically l...

5 months ago - GlobeNewsWire

EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphom...

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lo...

6 months ago - GlobeNewsWire

EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lo...

6 months ago - GlobeNewsWire

Should You Buy EQRx (EQRX) Ahead of Earnings?

EQRx (EQRx) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022

CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically ...

7 months ago - GlobeNewsWire

EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically ...

7 months ago - GlobeNewsWire

EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress

CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically ...

8 months ago - GlobeNewsWire

EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings

EQRx Inc (NASDAQ: EQRX), along with its partner CStone Pharmaceuticals has announced data from Phase 3 GEMSTONE-302 trial of sugemalimab plus chemotherapy as a first-line treatment for stage IV non-smal...

10 months ago - Benzinga

Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell ...

CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radicall...

10 months ago - GlobeNewsWire

EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Low...

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radicall...

10 months ago - GlobeNewsWire

EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radicall...

11 months ago - GlobeNewsWire

EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices

NEW YORK and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences III (Nasdaq: CMLT, CMLTW, CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affi...

11 months ago - GlobeNewsWire

Corvex, Casdin Backed SPAC To Merge With EQRx In $1.8B Deal

CM Life Sciences III Inc (NASDAQ: CMLT), the third SPAC backed by Eli Casdin's Casdin Capital LLC and Keith Meister's Corvex Management LP, is set to merge with EQRx Inc (NASDAQ: EQRX). The stock will l...

1 year ago - Benzinga

Here are the benefits of SPAC deals

Eli Casdin, the chief investment officer of Casdin Capital, joins Keith Meister, CEO of Corvex Management, on the Halftime Report to discuss their SPAC deal with EQRX, a biotechnology company.

1 year ago - CNBC Television